EOAI3402143
CAS No. 1699750-95-2
EOAI3402143( Deubiquitinase inhibitor G9 | EOAI 3402143 )
Catalog No. M12594 CAS No. 1699750-95-2
EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 75 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 222 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEOAI3402143
-
NoteResearch use only, not for human use.
-
Brief DescriptionEOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor.
-
DescriptionEOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor with increased aqueous solubility and greater cellular Usp9x inhibitory activity than WP1130; displays nM apoptotic activity against other myeloma cell lines and diffuse large B-cell lymphomas cells; increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice; also inhibis Usp5.
-
In VitroEOAI3402143 retains potent Usp9x and Usp5 inhibitory activity. EOAI3402143 dose-dependently inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis. Treatment of UM-2, UM-6, UM-16, and UM-76 with Usp9x inhibitor EOAI3402143 (G9) dose-dependently suppresses cell survival, while 600 nM of EOAI3402143 completely suppresses UM-2 3D colony growth when compared to untreated vehicle controls.
-
In VivoTo examine this potential, the effect of EOAI3402143 (G9) treatment is investigated on human MIAPACA2 tumor xenografts. Human MIAPACA2 cells are injected subcutaneously into NSG mice. Primary tumor development is monitored by caliper measurements, and once measurable, mice are separated into two groups and are treated with either vehicle control (PEG300/DMSO) or G9 at 15 mg/kg. Tumor growth, animal weight, behavior, and mobility are monitored during treatment. In parallel, murine 8041 tumors are also established and subjected to similar G9 treatment and tumor monitoring regimen as the human MIAPACA2 xenografts. Consistent with the in vitro findings, Usp9x inhibition results in the suppression of tumor growth in human tumor xenografts, but any significant effect on the growth of 8041 tumors xenografts is not observed, although the Usp9x activity is inhibited effectively by EOAI3402143 treatment in both human MIAPACA2 and mouse 8041 xenograft tumors.
-
SynonymsDeubiquitinase inhibitor G9 | EOAI 3402143
-
PathwayProteasome/Ubiquitin
-
TargetDUB
-
RecptorDUB
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1699750-95-2
-
Formula Weight503.424
-
Molecular FormulaC25H28Cl2N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL 99.32 mM; H2O : < 0.1 mg/mL
-
SMILESCCCC(C1=CC=C(C=C1)OCCN2CCOCC2)NC(=O)C(=CC3=C(C=CC(=N3)Cl)Cl)C#N
-
Chemical Name(E)-2-cyano-3-(3,6-dichloropyridin-2-yl)-N-(1-(4-(2-morpholinoethoxy)phenyl)butyl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Peterson LF, et al. Blood. 2015 Jun 4;125(23):3588-97.
2. Potu H, et al. Oncotarget. 2014 Jul 30;5(14):5559-69.
molnova catalog
related products
-
VLX1570
VLX1570 is a small molecule b-AP15 analog that fucttion as proteasome deubiquitinase inhibitor with IC50 of 10 uM.
-
HBX-19818
HBX-19818?is a?potent, selective USP7 inhibitor with IC50 of 28.1 uM.
-
SJB3-019A B
SJB3-019A is a potent, potent and novel ubiquitin-specific protease 1 (USP1) inhibitor, which promotes ID1 degradation and cytotoxicity in K562 cells 5 times more than SJB2-043, with IC50 of 0.0781 μM. SJB3-019A inhibits cell proliferation and causes cell apoptosis.
Cart
sales@molnova.com